Role of lung apolipoprotein A-I in idiopathic pulmonary fibrosis: Antiinflammatory and antifibrotic effect on experimental lung injury and fibrosis

American Journal of Respiratory and Critical Care Medicine

Volumn 182, Issue 5, 2010, Pages 633-642

  Kim, Tae Hoon ^a   Lee, Yoo Hoon ^a   Kim, Kyung Hun ^a   Lee, Shin Hwa ^a   Cha, Ji Yeon ^a   Shin, Eun Kyoung ^a   Jung, Seok ^a   Jang, An Soo ^a   Park, Sung Woo ^a   Uh, Soo Taek ^b   Kim, Young Hoon ^a   Park, Jai Soung ^a   Sin, Hwa Gyoun ^a   Youm, Wook ^b   Koh, Eun Suk ^a   Cho, Sun Young ^c   Paik, Young Ki ^c   Rhim, Tai Youn ^a,d   Park, Choon Sik ^a  

^a Soonchunhyang University   (South Korea)

^b Soonchunhyang University College of Medicine   (South Korea)

^c Yonsei University   (South Korea)

^d Hanyang University   (South Korea)

Author keywords

Apolipoprotein A I; Bleomycin A2; Fibrosis, pulmonary; Idiopathic interstitial pneumonia

Indexed keywords

ALPHA 1 ANTICHYMOTRYPSIN; ALPHA 1 ANTITRYPSIN; AMINOPEPTIDASE; AMINOPEPTIDASE PILS; ANGIOTENSINOGEN; APOLIPOPROTEIN A1; BETA ACTIN; BLEOMYCIN; CELL PROTEIN; CLUSTERIN; COLLAGEN; COMPLEMENT COMPONENT C4A; HAPTOGLOBIN; HEMOGLOBIN BETA CHAIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN J CHAIN; MACROPHAGE CAPPING PROTEIN; MYOSIN; MYOSIN 1D; PROTEIN DISULFIDE ISOMERASE; PROTEIN DISULFIDE ISOMERASE A3; UNCLASSIFIED DRUG; MESSENGER RNA;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL INFILTRATION; CLINICAL ARTICLE; CONTROLLED STUDY; DIFFERENTIAL DISPLAY; DOSE RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROSING ALVEOLITIS; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATORY CELL; LIQUID CHROMATOGRAPHY; LOCAL THERAPY; LUNG ALVEOLUS EPITHELIUM; LUNG ALVEOLUS MACROPHAGE; LUNG INJURY; LUNG LAVAGE; MALE; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SHAM PROCEDURE; TANDEM MASS SPECTROMETRY; TWO DIMENSIONAL ELECTROPHORESIS; WESTERN BLOTTING; ANIMAL; BIOSYNTHESIS; CHEMICALLY INDUCED DISORDER; CHEMISTRY; DISEASE MODEL; FOAM CELL; GENETICS; LUNG; LUNG FIBROSIS; METABOLISM; METHODOLOGY; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; TWO DIMENSIONAL GEL ELECTROPHORESIS;

AGED; ANIMALS; APOLIPOPROTEIN A-I; BLEOMYCIN; BLOTTING, WESTERN; BRONCHOALVEOLAR LAVAGE FLUID; DISEASE MODELS, ANIMAL; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOAM CELLS; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; LUNG; MALE; MICE; MIDDLE AGED; PROTEOMICS; PULMONARY FIBROSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 77957705241     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.200905-0659OC     Document Type: Article

References (59)

1. King TE Jr, Costabel U, Cordier J-F, doPico GA, du Bois RM, Lynch D, Lynch JP III, Myers JL, Panos RJ, Raghu G, et al. Idiopathic pulmonary fibrosis: diagnosis and treatment. Am J Respir Crit Care Med 2000;161:646-664.
2. Selman M, King TE, Pardo A. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med 2001;134:136-151. (Pubitemid 32096342)
3. Lim GI, Lee KH, Jeong SW, Uh ST, Jin SY, Lee DH, Park JS, Choi DL, Kang CH, Park CS. Clinical features of interstitial lung diseases. Korean J Intern Med 1996;11:113-121.
4. Wahidi MM, Schwartz DA, Raghu G. Genetics of familial pulmonary fibrosis and other variants. In: Lynch JP, editor. Idiopathic pulmonary fibrosis. New York: Marcel Dekker; 2004. pp. 31-54.
5. Garantziotis S, Steele MP, Schwartz DA. Pulmonary fibrosis: thinking outside of the lungs. J Clin Invest 2004;114:319-321.
6. Maher TM, Wells AU, Laurent GJ. Idiopathic pulmonary fibrosis: multiple causes and multiple mechanisms? Eur Respir J 2007;30:835-839.
7. Kinnula VL, Fattman CL, Tan RJ, Oury TD. Oxidative stress in pulmonary fibrosis: a possible role for redox modulatory therapy. Am J Respir Crit Care Med 2005;172:417-422.
8. Keane MP, Strieter RM, Belperio JA. Mechanisms and mediators of pulmonary fibrosis. Crit Rev Immunol 2005;25:429-463.
9. Kaminski N. Microarray analysis of idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol 2003;29(Suppl. 3):S32-S36.
10. Zuo F, Kaminski N, Eugui E, Allard J, Yakhini Z, Ben-Dor A, Lollini L, Morris D, Kim Y, DeLustro B, et al. Gene expression analysis reveals matrilysin as a key regulator of pulmonary fibrosis in mice and humans. Proc Natl Acad Sci U S A 2002;99:6292-6297. (Pubitemid 34493305)
11. Plymoth A, Lofdahl CG, Ekberg-Jansson A, Dahlback M, Lindberg H, Fehniger TE, Marko-Varga G. Human bronchoalveolar lavage: biofluid analysis with special emphasis on sample preparation. Proteomics 2003;3:962-972.
12. Lindahl M, Stahlbom B, Tagesson C. Newly identified proteins in human nasal and bronchoalveolar lavage fluids: potential biomedical and clinical applications. Electrophoresis 1999;20:3670-3676.
13. Rottoli P, Magi B, Perari MG, Liberatori S, Nikiforakis N, Bargagli E, Cianti R, Bini L, Pallini V. Cytokine profile and proteome analysis in bronchoalveolar lavage of patients with sarcoidosis, pulmonary fibrosis associated with systemic sclerosis and idiopathic pulmonary fibrosis. Proteomics 2005;5:1423-1430. (Pubitemid 40503057)
14. Rottoli P, Magi B, Cianti R, Bargagli E, Vagaggini C, Nikiforakis N, Pallini V, Bini L. Carbonylated proteins in bronchoalveolar lavage of patients with sarcoidosis, pulmonary fibrosis associated with systemic sclerosis and idiopathic pulmonary fibrosis. Proteomics 2005;5:2612-2618. (Pubitemid 40966488)
15. Lee YH, Kim KH, Kim TH, Lee SH, Cha JY, Jung S, Jang AS, Park SW, Uh ST, Kim YH, et al. Role of lung apolipoprotein A1 in idiopathic pulmonary fibrosis: anti-inflammatory and anti-fibrotic effect [abstract]. In: Proceedings of the 18th KOGO Conference. Seoul: Korea Genome Organization; 2009. pp. 108-109.
16. American Thoracic Society, European Respiratory Society. American Thoracic Society/European Respiratory Society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2002;165:277-304.
17. Park CS, Chung SW, Ki SY, Lim GI, Uh ST, Kim YH, Choi DI, Park JS, Lee DW, Kitaichi M. Increased levels of interleukin-6 are associated with lymphocytosis in bronchoalveolar lavage fluids of idiopathic nonspecific interstitial pneumonia. Am J Respir Crit Care Med 2000;162:1162-1168.
18. Bedrossian CW, Warren CJ, Ohar J, Bhan R. Amiodarone pulmonary toxicity: cytopathology, ultrastructure, and immunocytochemistry. Ann Diagn Pathol 1997;1:47-56.
19. Cha MH, Rhim T, Kim KH, Jang AS, Paik YK, Park CS. Proteomic identification of macrophage migration-inhibitory factor upon exposure to TiO2 particles. Mol Cell Proteomics 2007;6:56-63.
20. Han SJ, Kim JH, Noh YJ, Chang HS, Kim CS, Kim KS, Ki SY, Park CS, Chung IY. Interleukin (IL)-5 downregulates tumor necrosis factor (TNF)-induced eotaxin messenger RNA (mRNA) expression in eosinophils. Induction of eotaxin mRNA by TNF and IL-5 in eosinophils. Am J Respir Cell Mol Biol 1999;21:303-310.
21. Kazerooni EA, Martinez FJ, Flint A, Jamadar DA, Gross BH, Spizarny DL, Cascade PN, Whyte RI, Lynch JP III, Toews G. Thin-section CT obtained at 10 mm increments versus limited three-level thin-section CT for idiopathic pulmonary fibrosis: correlation with pathologic scoring. AJR Am J Roentgenol 1997;169:977-983.
22. Taskar VS, Coultas DB. Is idiopathic pulmonary fibrosis an environmental disease. Proc Am Thorac Soc 2006;3:293-298. (Pubitemid 43845405)
23. Nemery B, Bast A, Behr J, Borm PJ, Bourke SJ, Camus PH, De Vuyst P, Jansen HM, Kinnula VL, Lison D, et al. Interstitial lung disease induced by exogenous agents: factors governing susceptibility. Eur Respir J Suppl 2001;32:30s-42s.
24. Abboud RT, Vimalanathan S. Pathogenesis of COPD. Part I. The role of protease antiprotease imbalance in emphysema. Int J Tuberc Lung Dis 2008;12:361-367.
25. Dahl M, Hersh CP, Ly NP, Berkey CS, Silverman EK, Nordestgaard BG. The protease inhibitor PI*S allele and COPD: a meta-analysis. Eur Respir J 2005;26:67-76.
26. Geddes DM, Webley M, Brewerton DA, Turton CW, Turner-Warwick M, Murphy AH, Ward AM. Alpha 1-antitrypsin phenotypes in fibrosing alveolitis and rheumatoid arthritis. Lancet 1977;2:1049-1051.
27. Hubbard R, Baoku Y, Kalsheker N, Britton J, Johnston I. Alpha1-antitrypsin phenotypes in patients with cryptogenic fibrosing alveolitis: a case-control study. Eur Respir J 1997;10:2881-2883. (Pubitemid 28052805)
28. Nagareda T, Tanaka A, Terada N, Imakon Y, Shiomi H, Matsubara H, Noro A, Nishizawa Y. Suppressive effect of anti-alpha 1-antichymotrypsin serum on pulmonary fibrosis induced by phorbol myristate acetate in vivo. Lab Invest 1995;73:541-546.
29. Galbois A, Thabut D, Tazi KA, Rudler M, Mohammadi MS, Bonnefont-Rousselot D, Bennani H, Bezeaud A, Tellier Z, Guichard C, et al. Ex vivo effects of high-density lipoprotein exposure on the lipopolysaccharide-induced inflammatory response in patients with severe cirrhosis. Hepatology 2009;49:175-184.
30. Anderson NL, Anderson NG. The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics 2002;1:845-867.
31. Ishii H, Mukae H, Kadota J, Fujii T, Abe K, Ashitani J, Kohno S. Increased levels of interleukin-18 in bronchoalveolar lavage fluid of patients with idiopathic nonspecific interstitial pneumonia. Respiration 2005;72:39-45.
32. Yan YJ, Li Y, Lou B, Wu MP. Beneficial effects of ApoA-I on LPS-induced acute lung injury and endotoxemia in mice. Life Sci 2006;79:210-215.
33. Van Lenten BJ, Wagner AC, Navab M, Anantharamaiah GM, Hui EK, Nayak DP, Fogelman AM. D-4F, an Apo A1 mimetic peptide, inhibits the inflammatory response induced by influenza A infection of human type II pneumocytes. Circulation 2004;110:3252-3258.
34. Bolanos-Garcia VM, Miguel RN. On the structure and function of apolipoproteins: more than a family of lipid-binding proteins. Prog Biophys Mol Biol 2003;83:47-68.
35. Chau P, Fielding PE, Fielding CJ. Bone morphogenetic protein-1 (BMP-1) cleaves human proapolipoprotein A1 and regulates its activation for lipid binding. Biochemistry 2007;46:8445-8450. (Pubitemid 47075981)
36. Edelstein C, Gordon JI, Toscas K, Sims HF, Strauss AW, Scanu AM. In vitro conversion of proapoprotein A-I to apoprotein A-I. Partial characterization of an extracellular enzyme activity. J Biol Chem 1983;258:11430-11433.
37. de Torre C, Ying SX, Munson PJ, Meduri GU, Suffredini AF. Proteomic analysis of inflammatory biomarkers in bronchoalveolar lavage. Proteomics 2006;6:3949-3957.
38. Wattiez R, Hermans C, Cruyt C, Bernard A, Falmagne P. Human bronchoalveolar lavage fluid protein two-dimensional database: study of interstitial lung diseases. Electrophoresis 2000;21:2703-2712.
39. Magi B, Bini L, Perari MG, Fossi A, Sanchez JC, Hochstrasser D, Paesano S, Raggiaschi R, Santucci A, Pallini V, et al. Bronchoalveolar lavage fluid protein composition in patients with sarcoidosis and idiopathic pulmonary fibrosis: a two-dimensional electrophoretic study. Electrophoresis 2002;23:3434-3444.
40. Fietta AM, Bardoni AM, Salvini R, Passadore I, Morosini M, Cavagna L, Codullo V, Pozzil E, Meloni F, Montecucco C. Analysis of bronchoalveolar lavage fluid proteome from systemic sclerosis patients with or without functional, clinical and radiological signs of lung fibrosis. Arthritis Res Ther 2006;8:R160 10.1186/ar2067.
41. Fitzgerald ML, Mendez AJ, Moore KJ, Andersson LP, Panjeton HA, Freeman MW. ATP-binding cassette transporter A1 contains an NH2-terminal signal anchor sequence that translocates the protein's first hydrophilic domain to the exoplasmic space. J Biol Chem 2001;276:15139-15145.
42. Lawn RM, Wade DP, Couse TL, Wilcox JN. Localization of human ATP-binding cassette transporter 1 (ABC1) in normal and atherosclerotic tissues. Arterioscler Thromb Vasc Biol 2001;21:378-385.
43. Bortnick AE, Favari E, Tao JQ, Francone OL, Reilly M, Zhang Y, Rothblat GH, Bates SR. Identification and characterization of rodent ABCA1 in isolated type II pneumocytes. Am J Physiol Lung Cell Mol Physiol 2003;285:L869-L878.
44. Bates SR, Tao JQ, Yu KJ, Borok Z, Crandall ED, Collins HL, Rothblat GH. Expression and biological activity of ABCA1 in alveolar epithelial cells. Am J Respir Cell Mol Biol 2008;38:283-292.
45. McNeish J, Aiello RJ, Guyot D, Turit T, Gabel C, Aldinger C, Hoppe KL, Roach ML, Royer LJ, de Wet J, et al. High density lipoprotein deficiency and foam cell accumulation in mice with targeted disruption of ATP-binding cassette transporter-1. Proc Natl Acad Sci U S A 2000;97:4245-4250.
46. Yamashita S, Sakai N, Hirano K, Ishigami M, Maruyama T, Nakajima N, Matsuzawa Y. Roles of plasma lipid transfer proteins in reverse cholesterol transport. Front Biosci 2001;6:D366-D387.
47. Moore BB, Hogaboam CM. Murine models of pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 2008;294:L152-L160.
48. Moeller A, Ask K, Warburton D, Gauldie J, Kolb M. The bleomycin animal model: a useful tool to investigate treatment options for idiopathic pulmonary fibrosis? Int J Biochem Cell Biol 2008;40:362-382.
49. Chenaud C, Merlani PG, Roux-Lombard P, Burger D, Harbarth S, Luyasu S, Graf JD, Dayer JM, Ricou B. Low apolipoprotein A-I level at intensive care unit admission and systemic inflammatory response syndrome exacerbation. Crit Care Med 2004;32:632-637.
50. Jiao YL, Wu MP. Apolipoprotein A-I diminishes acute lung injury and sepsis in mice induced by lipoteichoic acid. Cytokine 2008;43:83-87.
51. Hsieh GR, Schnickel GT, Garcia C, Shefizadeh A, Fishbein MC, Ardehali A. Inflammation/oxidation in chronic rejection: apolipoprotein A-I mimetic peptide reduces chronic rejection of transplanted hearts. Transplantation 2007;84:238-243. (Pubitemid 47205758)
52. Li Y, Dong JB, Wu MP. Human ApoA-I overexpression diminishes LPS-induced systemic inflammation and multiple organ damage in mice. Eur J Pharmacol 2008;590:417-422.
53. Liao XL, Lou B, Ma J, Wu MP. Neutrophils activation can be diminished by apolipoprotein A-I. Life Sci 2005;77:325-335. (Pubitemid 40692871)
54. Shi N, Wu MP. Apolipoprotein A-I attenuates renal ischemia/reperfusion injury in rats. J Biomed Sci 2008;15:577-583.
55. Kim KD, Lim HY, Lee HG, Yoon DY, Choe YK, Choi I, Paik SG, Kim YS, Yang Y, Lim JS. Apolipoprotein A-I induces IL-10 and PGE2 production in human monocytes and inhibits dendritic cell differentiation and maturation. Biochem Biophys Res Commun 2005;338:1126-1136.
56. Richter AG, McKeown S, Rathinam S, Harper L, Rajesh P, McAuley DF, Heljasvaara R, Thickett DR. Soluble endostatin is a novel inhibitor of epithelial repair in idiopathic pulmonary fibrosis. Thorax 2009;64:156-161.
57. Bargagli E, Olivieri C, Prasse A, Bianchi N, Magi B, Cianti R, Bini L, Rottoli P, Calgranulin B. S100A9) levels in bronchoalveolar lavage fluid of patients with interstitial lung diseases. Inflammation 2008;31:351-354.
58. Huh JW, Kim DS, Oh YM, Shim TS, Lim CM, Lee SD, Koh Y, Kim WS, Kim WD, Kim KR. Is metalloproteinase-7 specific for idiopathic pulmonary fibrosis? Chest 2008;133:1101-1106.
59. Baran CP, Opalek JM, McMaken S, Newland CA, O'Brien JM Jr, Hunter MG, Bringardner BD, Monick MM, Brigstock DR, Stromberg PC, et al. Important roles for macrophage colony-stimulating factor, CC chemokine ligand 2, and mononuclear phagocytes in the pathogenesis of pulmonary fibrosis. Am J Respir Crit Care Med 2007;176:78-89.